CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 66 enrolled
Drug / intervention
Ropivacaine 0.35%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03154658
NCT03154658Phase 4Completed
CompareCT.gov

Serratus Anterior Plane Block: Sub-Serratus vs Supra-Serratus Plane Block for Pain Control in Patients Undergoing Mastectomy

University of Texas Southwestern Medical Center·interventional·Posted May 16, 2017·Updated Mar 16, 2021

In Brief

A Phase 4 clinical trial evaluating Ropivacaine 0.35% for Pain, Post-operative. Completed, enrolled 66 participants across 1 site.

Detailed Summary

This is a randomized, interventional prospective study. Patients (n=66) undergoing mastectomies with or without tissue expander will be randomized to receive a supra-serratus or sub-serratus regional plane block prior to surgery. The main effect to be measured is total opioid consumption 24 hours after the operation. Secondary endpoints include measuring a change between pre-and post-operative pain scores, patient satisfaction of pain control during first 24 hours after the operation, presence of postoperative nausea and vomiting, duration of sleep on first postoperative night, and block performance time and length of stay, between the two treatment arms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Post-operative
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 16, 2017
Enrollment StartApr 1, 2017
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.1 years ago

Interventions

Ropivacaine 0.35%drug

The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.